LOGIN  |  REGISTER
Viking Therapeutics

Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

February 26, 2024 | Last Trade: US$3.38 0.06 1.66

FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on March 12, 2024 to discuss the Company’s business and financial results.

Fourth Quarter and Full Year 2023 Conference Call and Webcast Details:

  • What: Clover Health Fourth Quarter and Full Year 2023 Earnings Conference Call
  • When: Tuesday, March 12, 2024, at 5:00 p.m. Eastern Time
  • Dial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ423
  • Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of the Company’s website at https://investors.cloverhealth.com/ for 12 months

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page